Berwyn, Pennsylvania, November 2, 2015 – Maria Maccecchini, PhD, President and CEO of QR Pharma, Inc. is presenting a paper entitled “Analysis of Multiple Biomarkers and Factors in Blood and CSF in Phase 2 to Facilitate Choice of End Points in Phase 3” is part of a Forum on CNS Clinical Trials. The presentation is focused on the difficulties associated with clinical trials in Alzheimer’s disease and proposes a strategy to optimize development of its lead compound, Posiphen®.
The Forum addresses the slowing of drug approval, the exorbitant failure rate in CNS clinical trials and how to position CNS drugs for success. The event runs from November 2 to 3, 2015, in Bethesda, MD, and Dr. Maccecchini’s talk is on Monday, November 2, 2015 at 11:45 AM.
About QR Pharma, Inc.
Headquartered in Berwyn, Pennsylvania, QR Pharma, Inc. is a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment in neurological disorders.
QR is currently developing Posiphen as a disease-modifying drug for acute as well as chronic neurodegeneration and BNC for advanced Alzheimer’s disease. For more information on QR Pharma, please visit the company’s website, www.qrpharma.com
Contact: Maria Maccecchini
Tel: 610-727 3710
Fax: 610 727 4001